Search

Your search keyword '"Tamari, Roni"' showing total 729 results

Search Constraints

Start Over You searched for: Author "Tamari, Roni" Remove constraint Author: "Tamari, Roni"
729 results on '"Tamari, Roni"'

Search Results

3. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation

4. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group

5. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation

6. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

7. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

8. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines

10. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant

13. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study

14. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

15. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation

16. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant

17. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy

19. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation

20. Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

21. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

22. Budesonide Use for Grade 2 Gastrointestinal Graft-Versus-Host Disease after Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

23. High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

24. Early CD4 and B Cell Immune Reconstitution As Predictors of Outcomes in T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

27. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry

28. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

29. Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin

30. Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation

32. Survival following allogeneic transplant in patients with myelofibrosis

33. Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease

34. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

35. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor

36. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

38. Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant

39. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy

41. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies

42. Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

44. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis

45. T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML

46. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia

47. The Simplified Comorbidity Index predicts non‐relapse mortality in reduced‐intensity conditioning allogeneic haematopoietic cell transplantation

48. Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse

Catalog

Books, media, physical & digital resources